Riboflavin for Health & Longevity

Evidence Review created on 10/08/2026 using AI4L + evidence-mcp / Sonnet 5.5

Also known as: Vitamin B2, Lactoflavin, Riboflavin 5’-phosphate, Flavin mononucleotide, FMN

Motivation

Riboflavin (vitamin B2) is a water-soluble vitamin that cells convert into two helper molecules used in energy production and in antioxidant defense. It occurs naturally in dairy products, eggs, meat and green vegetables, and it is also sold as a single supplement and as part of multivitamins and B-vitamin blends. Its place in basic metabolism makes it a recurring candidate in health and longevity discussions.

Riboflavin was identified in the early twentieth century as an essential nutrient, and flour and bread enrichment programs later added it to staple foods. Research attention has since extended to daily amounts far above the dietary requirement, studied for migraine prevention, and to blood pressure in people carrying a common gene variant. Animal studies of aging have examined both added and restricted riboflavin.

This review examines the human and laboratory evidence on riboflavin for health and longevity in health-oriented adults. It covers the mechanism, the benefits and risks that have been studied, the amounts used in trials, interactions, monitoring and ongoing research, so that the strength of each claim can be set against the quality of the evidence behind it.

Benefits - Risks - Protocol - Conclusion

Expert commentary and narrative reviews that give a high-level overview of riboflavin.

No riboflavin-specific content was found on the sites of Peter Attia, Chris Kresser or Lifespan.io, and none on Andrew Huberman’s site beyond a segment of a guest episode whose official page could not be located; Rhonda Patrick and Life Extension are each represented by one item. Four items are listed rather than five because no further source gave a high-level overview of riboflavin; the remaining PubMed results were narrow experiments (for example, a roundworm depletion study) and were left out rather than padding the list.

Grokipedia

Riboflavin

Encyclopedia-style overview of riboflavin chemistry, nomenclature, coenzyme roles, dietary sources, deficiency signs and safety; AI-generated and cited to secondary sources.

Examine

Riboflavin (Vitamin B2)

Evidence-graded overview covering studied doses (1.6 to 400 mg daily), migraine, blood pressure and other outcomes, with a research feed.

ConsumerLab

B Vitamin Supplements Review (B Complexes, B6, B12, Biotin, Folate, Niacin, Riboflavin & More)

Independent product testing of B-complex and single B vitamin supplements, including riboflavin products; full results and ratings are limited to members.

Systematic Reviews

Systematic reviews (structured searches of the literature) and meta-analyses (statistical pooling of study results) of oral riboflavin, including pooled randomized trials (participants assigned to treatment or placebo by chance), selected from PubMed for recency, size and relevance.

No systematic review or meta-analysis of riboflavin adverse effects was found on PubMed, so the principal-risk category is unrepresented in this list.

Mechanism of Action

Riboflavin is absorbed in the small intestine through dedicated transporter proteins (a transporter deficiency review). Cells convert it to flavin mononucleotide (FMN) and then mostly to flavin adenine dinucleotide (FAD), coenzymes (helper molecules) of flavoproteins (enzymes that shuttle electrons) (a National Academies report). Proposed mechanisms:

  • Energy production: FAD works in the mitochondrial electron transport chain (the enzyme assembly that generates cellular energy); a brain energy deficit is the rationale for migraine prevention (Schoenen et al., 1998).
  • Folate and homocysteine metabolism: MTHFR (methylenetetrahydrofolate reductase, the enzyme supplying the folate form that recycles homocysteine) needs FAD; its common 677C→T variant loses FAD easily, so riboflavin may stabilize the enzyme in carriers of two copies, the TT genotype (CC and CT carry no or one copy) (McNulty et al., 2006).
  • Antioxidant recycling: FAD-dependent glutathione reductase regenerates glutathione (a main cellular antioxidant).
  • Other vitamins: FMN activates vitamin B6 and FAD supports niacin formation.

A competing view: partial riboflavin depletion extended roundworm lifespan through a mild stress response (Yerevanian et al., 2022).

Pharmacology: up to 27 mg is absorbed per dose, absorption half-life 1.1 hours (Zempleni et al., 1996); the enzymes flavokinase and FAD synthetase make FMN and FAD (a National Academies report), which are stored in limited amounts in liver, spleen, kidneys and heart, and plasma half-life is about 66 to 84 minutes (a drug monograph). As a coenzyme precursor, riboflavin has no drug-target selectivity.

Historical Context & Evolution

Riboflavin was first described in 1879 as a yellow pigment in milk (a review of riboflavin’s health effects), and wheat flour and bread have been enriched with it in the United States since 1943 (a Linus Pauling Institute review). Its original intended use was nutritional: preventing ariboflavinosis (riboflavin deficiency), whose signs include sore throat, cracked lips and mouth corners, a purple-red sore tongue (glossitis), scaly skin inflammation and anemia (a National Academies report), defined in controlled human depletion studies of the 1940s and 1950s (Horwitt et al., 1950).

Interest in health optimization grew from three directions. Biochemistry showed FAD-dependent enzymes in energy production and antioxidant recycling. An open pilot study of 400 mg daily in migraine (Schoenen et al., 1994) preceded a placebo-controlled trial (Schoenen et al., 1998), and the American Academy of Neurology (a physician society; no direct member revenue from riboflavin identified) later rated riboflavin probably effective for migraine prevention (Holland et al., 2012). From 2006, Northern Ireland trials tied the MTHFR 677TT genotype to riboflavin-responsive homocysteine and blood pressure (McNulty et al., 2006; Horigan et al., 2010); a later conference abstract was funded by the riboflavin producer DSM (Ward et al., 2019).

Opinion has not settled. A 2025 Cochrane review judged the blood pressure evidence very uncertain because of small, high-risk-of-bias trials (Bradbury et al., 2025), while the original investigators report genotype-specific effects, and trials in children split between benefit (Talebian et al., 2018) and no effect (MacLennan et al., 2008).

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no outcome is shown in placebo-controlled trials from more than one independent research group, as the migraine data center on one group’s trial and the blood pressure and homocysteine data on one Ulster group.

Medium 🟩 🟩

Migraine Prevention in Adults ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

At 400 mg daily for three months, riboflavin reduced attack frequency versus placebo (Schoenen et al., 1998), and pooled trials favor riboflavin (Amini et al., 2026). Children’s trials disagree: benefit at a high dose (Talebian et al., 2018), none at 200 mg (MacLennan et al., 2008) or 50 mg (Bruijn et al., 2010). A riboflavin-magnesium-feverfew combination matched a 25 mg riboflavin placebo (Maizels et al., 2004). This bears on symptom management in established migraine, not healthy aging. Net reading: modest benefit in adults, inconsistent elsewhere.

Magnitude: 59% of patients on riboflavin versus 15% on placebo improved by at least 50% in headache days, a number needed to treat (patients treated for one extra responder) of 2.3, in 55 patients (Schoenen et al., 1998); pooled attack frequency 1.39 lower than control (95% confidence interval, CI, the range likely to contain the true value: 0.25 to 2.52 lower) across 12 trials (Amini et al., 2026).

Hemoglobin Response in Riboflavin-Deficient Adults

In 119 young women with biochemical riboflavin deficiency, 2 or 4 mg daily for eight weeks improved riboflavin status versus placebo; hemoglobin gains tracked that improvement and were largest in the lowest-status third (Powers et al., 2011). Adding 1 to 5 mg daily to iron and folic acid also tended to improve anemia measures in two trials of anemic pregnant women (Ma et al., 2008; Suprapto et al., 2002), but vitamin A arms and pregnancy make those trials indirect. The benefit applies to low riboflavin status.

Magnitude: direction only: hemoglobin rose more with improved riboflavin status, and significantly more in women with the lowest baseline status; the source abstract reports no group-difference figure (Powers et al., 2011). In pregnancy, hemoglobin was 5.4 g/L higher with riboflavin plus vitamin A plus iron and folic acid than with iron and folic acid alone (combination, not riboflavin alone) (Ma et al., 2008).

Low 🟩

Blood Pressure Lowering in Adults With the MTHFR 677TT Genotype ⚠️ Conflicted

Daily 1.6 mg lowered systolic pressure in 677TT adults (Wilson et al., 2013) but not CC or CT patients (Horigan et al., 2010). A Cochrane review pooling a 10 mg abstract (Ward et al., 2019) rated the evidence very uncertain (Bradbury et al., 2025). Net reading: promising, unconfirmed, genotype-specific.

Magnitude: 5.6 mmHg (millimeters of mercury) lower systolic pressure than placebo (±2.6; P = 0.033, the probability of so large a difference arising by chance) in 91 adults with hypertension and the TT genotype (Wilson et al., 2013); Cochrane: TT subgroup 4.76 mmHg lower (95% CI 0.09 to 9.43 lower, 188 participants), all participants 1.94 mmHg lower (CI 5.74 lower to 1.86 higher) (Bradbury et al., 2025).

Nuclear Cataract Prevalence in Nutritionally Deficient Older Adults

In a rural China trial, riboflavin plus niacin lowered the prevalence of nuclear cataract (clouding at the lens center), mostly in ages 65 to 74, with no effect on cortical cataract (edge clouding) (Sperduto et al., 1993). The niacin pairing and deficient population make this indirect.

Magnitude: 44% lower prevalence of nuclear cataract at ages 65 to 74 with riboflavin and niacin than without (Sperduto et al., 1993).

Depression Risk (Dietary Intake)

Pooled observational studies associate higher dietary riboflavin intake with lower depression risk, significant in females but not males (Wu et al., 2022). Food-based intake, confounding (other lifestyle factors mixed into the association) and the absence of supplement trials make this indirect.

Magnitude: relative risk (ratio of risk between groups) 0.77 (95% CI 0.67 to 0.89) for highest versus lowest dietary intake; females 0.80 (0.64 to 0.99), males 0.83 (0.67 to 1.02) (Wu et al., 2022).

Dementia Risk (Dietary Intake)

A Japanese cohort of 4,171 adults aged 40 to 69 had fewer cases of disabling dementia with higher dietary riboflavin intake over 15 years (Kishida et al., 2025). Intake came from one 24-hour recall of food, so the evidence is observational and indirect.

Magnitude: hazard ratio (ratio of event rates between groups) 0.51 (95% CI 0.42 to 0.63) for the highest versus lowest quarter of intake (Kishida et al., 2025).

Breast Cancer Risk (Dietary Intake)

Pooled observational studies weakly associate higher dietary riboflavin intake with lower breast cancer incidence in women (Yu et al., 2017). Food-based intake, confounding and the absence of supplement trials make this indirect.

Magnitude: relative risk 0.85 (95% CI 0.76 to 0.95) for highest versus lowest dietary intake across ten studies (Yu et al., 2017).

Colorectal Cancer Risk (Riboflavin Intake)

Pooled observational studies associate higher riboflavin intake, from food and supplements combined, with lower colorectal cancer incidence (Ben et al., 2019). Mixed intake sources, confounding and the absence of supplement trials make this indirect.

Magnitude: relative risk 0.87 (95% CI 0.81 to 0.93) for higher versus lower intake across 14 studies; total intake from diet and supplements 0.86 (95% CI 0.78 to 0.94); dietary intake alone 0.89 (95% CI 0.82 to 0.98) (Ben et al., 2019).

Motor Function in Parkinson’s Disease ⭕️ Not Central to Health & Longevity

An uncontrolled series of 19 patients given 90 mg daily plus removal of red meat improved motor scores over six months (Coimbra & Junqueira, 2003). The diet change confounds the result; the item bears on symptom management in established Parkinson’s disease, not healthy aging.

Magnitude: motor capacity rose from 44% to 71% over six months (no control group; riboflavin and diet change combined) (Coimbra & Junqueira, 2003).

Riboflavin-Responsive Inherited Disorders ⭕️ Not Central to Health & Longevity

Case series report improvement with riboflavin in inherited disorders such as riboflavin transporter deficiency (a nerve disorder) (a transporter deficiency review) and, with carnitine, lipid-storage myopathy (fat-laden muscle disease) in three patients aged 67 to 71 (Sadeh et al., 2024). This bears on rare genetic disease, not healthy aging.

Magnitude: Not quantified in available studies. Only case reports and uncontrolled case series exist, with no comparison groups.

Disability in Multiple Sclerosis ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

A placebo-controlled trial of 10 mg daily in 29 patients found no disability benefit (Naghashpour et al., 2013); a review of mixed studies judged it supportive (Naghashpour et al., 2017). This bears on symptom management in established multiple sclerosis (nerve-insulation damage), not healthy aging. Net reading: no controlled benefit shown.

Magnitude: Expanded Disability Status Scale (a 0 to 10 disability rating) fell from 2.3 to 1.6 with riboflavin and from 2.8 to 2.3 with placebo; the difference between groups was not significant, and the abstract reports no confidence interval (Naghashpour et al., 2013).

Speculative 🟨

Plasma Homocysteine Lowering in MTHFR 677TT Adults ⚠️ Conflicted

Homocysteine fell in 677TT adults (McNulty et al., 2006) and, at 10 mg, in low-status older adults (Tavares et al., 2009) but not at 1.6 mg (McKinley et al., 2002). Net reading: dose- and genotype-dependent.

Lifespan in Invertebrates ⚠️ Conflicted

Lifelong riboflavin supplementation extended fruit fly lifespan (Zou et al., 2017), whereas partial depletion extended roundworm lifespan (Yerevanian et al., 2022). No mammalian or human lifespan data exist. Net reading: opposing invertebrate signals.

Telomere Length

Among 3,788 US adults aged 45 and over, higher dietary riboflavin intake was weakly associated with longer telomeres (chromosome end caps), mainly in women (Chen et al., 2022). Telomere length is an unvalidated marker.

Benefit-Modifying Factors

  • Genetic polymorphisms: MTHFR 677TT, found in about 12% of adults in an Irish cohort, is the genotype in which blood pressure and homocysteine responses appeared; CC and CT adults (no or one variant copy) showed none (Horigan et al., 2010; Ward et al., 2020).
  • Baseline biomarker levels: Homocysteine fell 40% in 677TT adults with lower baseline status versus 22% overall (McNulty et al., 2006); older adults with abnormal EGRAC (erythrocyte glutathione reductase activation coefficient, a status blood test) improved on 1.6 or 25 mg (Madigan et al., 1998).
  • Sex differences: The depression and telomere associations were significant in women (Wu et al., 2022; Chen et al., 2022); absorption and elimination did not differ by sex (Zempleni et al., 1996). Sex-specific supplement trials are lacking.
  • Pre-existing health conditions: Hypertension on drug therapy, iron-deficiency anemia and migraine defined the trial populations; alcohol use, hypothyroidism and adrenal insufficiency (low adrenal hormone output) raise deficiency risk, so correcting low status is most plausible there (a Linus Pauling Institute review).
  • Age: About 49% of free-living adults aged 65 and older had abnormal EGRAC despite adequate reported intake (Madigan et al., 1998); the TT-associated hypertension risk appeared from ages 18 to 70 (Ward et al., 2020).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no specific adverse event is documented in controlled trials from more than one independent research group.

Medium 🟥 🟥

No risk reaches Medium: the only excess over placebo in a controlled trial came from riboflavin given together with niacin, which is indirect evidence for riboflavin alone.

Low 🟥

Mild Gastrointestinal Upset and Frequent Urination at High Doses ⚠️ Conflicted

Diarrhea and polyuria (frequent urination) occurred in two riboflavin patients at 400 mg, abdominal cramps in one placebo patient (Schoenen et al., 1998); side effects were fewer than with valproate (Rahimdel et al., 2015). Cochrane found little to no difference (Bradbury et al., 2025). Net reading: no demonstrated excess.

Magnitude: 2 events with riboflavin versus 1 with placebo among 55 patients at 400 mg (Schoenen et al., 1998); the Cochrane analysis reports the same trial (2 versus 1, 54 participants) (Bradbury et al., 2025).

Bright Yellow Urine (Flavinuria)

High-dose riboflavin turns urine bright yellow, which is considered harmless (a Linus Pauling Institute review). In a Brazilian series of Parkinson’s patients taking 90 mg daily, yellowish urine was the only side effect observed (Coimbra & Junqueira, 2003).

Magnitude: the only side effect reported among 19 patients on 30 mg three times daily; no control group and no rate reported (Coimbra & Junqueira, 2003).

Posterior Subcapsular Cataract With Riboflavin Plus Niacin

In the Linxian trial, riboflavin plus niacin was associated with a statistically significant increase in posterior subcapsular cataract (clouding at the back of the lens) (Sperduto et al., 1993). Case numbers were very small, and niacin cannot be separated from riboflavin.

Magnitude: direction only: higher prevalence with riboflavin plus niacin (about 3 mg and 40 mg daily for 5 to 6 years); the source abstract reports no outcome figure (Sperduto et al., 1993).

Speculative 🟨

Photosensitization of Lens Proteins

In test-tube experiments, riboflavin with sunlight crosslinked and damaged lens proteins, an effect offset by ascorbic acid and glutathione (Anbaraki et al., 2016). No human data link supplemental riboflavin to lens damage.

Support of Cancer-Cell Growth in Cell Models

Leukemia cells depend on riboflavin for nucleotide synthesis (making DNA units) (Bjelosevic et al., 2025); riboflavin supports cancer-cell resistance to ferroptosis (iron-dependent cell death) (Skafar et al., 2026). No human data show cancer promotion.

DNA Strand Breaks With Chromium (VI) in Cell Culture

In cell-culture studies, excess riboflavin may increase DNA strand breaks in the presence of chromium (VI), a known carcinogen (a Linus Pauling Institute review). No human data are available.

High-Dose Use in Pregnancy and Lactation

Safety data for high-dose riboflavin in pregnancy are lacking (Examine). Dosages above the recommended intake fall in pregnancy Category C (risk cannot be ruled out), and riboflavin enters breast milk (a drug monograph).

Risk-Modifying Factors

  • Genetic polymorphisms: No variant is known to increase harm from supplemental riboflavin. G6PD deficiency (an inherited lack of the red-cell enzyme that guards against oxidative damage) invalidates the EGRAC status test (a National Academies report).
  • Baseline biomarker levels: Absorption saturates near 27 mg per dose and excess is excreted in urine, so replete adults accumulate little (Zempleni et al., 1996); no baseline level is known to raise risk.
  • Sex differences: Absorption and elimination showed no sex differences (Zempleni et al., 1996); no sex-specific harms are reported.
  • Pre-existing health conditions: Hepatitis, cirrhosis and biliary obstruction (blocked bile flow) decrease absorption, and dialysis may raise needs (a drug monograph). Leukemia cells depend on riboflavin in cell studies (Bjelosevic et al., 2025); human data are absent.
  • Age: Older adults more often have low status (Madigan et al., 1998); no age-specific harm signal has been reported in trials of older participants.

Key Interactions & Contraindications

Prescription medications

  • Probenecid (gout drug): monitor. Decreases riboflavin absorption, which may lower status (Jusko & Levy, 1967; a drug monograph). Mitigation: EGRAC check if used long term.
  • Phenothiazines and tricyclic antidepressants (antipsychotic and antidepressant classes; chlorpromazine, amitriptyline, imipramine): caution. Chlorpromazine promotes urinary riboflavin loss in animals and humans (a review of drugs that promote riboflavin excretion); tricyclic inhibition of flavin conversion is (theoretical). Consequence: lower riboflavin status.
  • Anthracyclines (chemotherapy class; doxorubicin): caution (theoretical). Reported to inhibit conversion of riboflavin to its coenzymes (a Linus Pauling Institute review); consequence: reduced flavin supply.
  • Barbiturate anticonvulsants (seizure-prevention class; phenobarbital): monitor (theoretical). Long-term use may increase liver breakdown of riboflavin, raising deficiency risk (a Linus Pauling Institute review).
  • Oral contraceptives (ethinylestradiol combinations): monitor. Deficiency by EGRAC in 24 of 56 users versus 11 of 100 non-users (Newman et al., 1978), but no difference with controlled diet (a National Academies report) or adequate nutrition (Carrigan et al., 1979): conflicting.
  • Antihypertensive drugs (blood pressure-lowering class; amlodipine, lisinopril, hydrochlorothiazide): monitor. In premature cardiovascular disease patients, 82% on antihypertensives, 1.6 mg riboflavin lowered blood pressure further in the 677TT group (Horigan et al., 2010); excessive lowering is possible (theoretical). Mitigation: blood pressure log.
  • Aminoglycosides, erythromycin and bleomycin (antibiotic and chemotherapy drugs; streptomycin, kanamycin, erythromycin): caution (theoretical). Infusion-product labeling lists possibly decreased antibiotic activity or in vitro bleomycin inactivation; oral supplements are unstudied (a drug monograph).
  • Propantheline (anticholinergic, a drug that slows gut movement): minor. Delays riboflavin absorption but increases the total absorbed (Levy et al., 1972; a drug monograph); no action is described.
  • Ticagrelor (antiplatelet drug): minor. Raised peak plasma riboflavin 1.20-fold (90% CI 1.10 to 1.32) versus placebo in healthy volunteers, probably by inhibiting an intestinal transporter (Deng et al., 2024); clinical significance is unknown.

Over-the-counter medications

  • Boric acid–containing antiseptics and insecticides: caution. Boric acid ingestion greatly increased urinary riboflavin excretion in about two thirds of 14 poisoning patients (Pinto et al., 1978); consequence: depletion. Mitigation: avoiding ingestion.
  • Aluminum and magnesium hydroxide antacids: minor. Delayed the time of peak urinary riboflavin excretion without changing total excretion in five subjects (Feldman & Hedrick, 1983); consequence: slower absorption; no action is described.
  • Urine color tests, fluorometric catecholamine and urobilinogen assays (laboratory tests): monitor. Riboflavin may cause color interference or false elevations (a drug monograph); consequence: misleading results.

Supplements

  • Folic acid: monitor. A 400 µg folic acid supplement raised the share of adults with deficient-range EGRAC from 52% to 65% (Moat et al., 2003); consequence: higher riboflavin demand. Mitigation: confirm riboflavin adequacy.
  • Vitamin B6: no caution (complementary). Riboflavin at 1.6 to 25 mg improved low pyridoxal 5’-phosphate (the active B6 form) in older adults with low status (Madigan et al., 1998).
  • Niacin (nicotinic acid, nicotinamide): caution. The only riboflavin–niacin trial linked the pair to posterior subcapsular cataract (Sperduto et al., 1993); no mitigation has been tested.
  • Boron supplements (boric acid, sodium borate): caution (theoretical), same mechanism as boric acid above (Pinto et al., 1978); consequence: riboflavin depletion.
  • Iron: no caution (complementary). Adding riboflavin tended to improve the hemoglobin response to iron in anemic pregnant women (Suprapto et al., 2002).
  • Magnesium and coenzyme Q10 (additive effects): no caution. Used with riboflavin in a migraine trial (Gaul et al., 2015); no interaction in absorption or elimination identified, and an additive effect is untested.

Other interventions

  • Alcohol: monitor. Chronic intake is associated with riboflavin deficiency through impaired intake and absorption (a Linus Pauling Institute review); consequence: low status.
  • Strenuous exercise: monitor. About 20% more riboflavin was needed to normalize status in exercising women (a National Academies report).

Populations who should avoid Riboflavin:

  • People with known hypersensitivity (allergy) to riboflavin or any ingredient in the formulation (labeling cited in a drug monograph)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Doses within the studied range: Trials used 1.6 to 400 mg daily and no tolerable upper intake level (highest daily intake unlikely to cause harm) was set (a National Academies report); staying within studied amounts limits untested high-dose exposure.
  • Divided doses with food: Absorption rises with food (a drug monograph) and saturates near 27 mg per dose (Zempleni et al., 1996); dividing larger daily amounts limits wasted dose and the gastrointestinal events seen at 400 mg.
  • Status testing around long-term use: EGRAC at baseline and at 12 to 16 weeks limits supplementation beyond need; a coefficient of 1.40 or higher marks deficiency (a review of riboflavin status and anemia).
  • Blood pressure log with antihypertensive drugs: limits unnoticed additive lowering in 677TT adults (Horigan et al., 2010).
  • Avoiding the riboflavin–niacin pairing: the only paired trial raised posterior subcapsular cataract; whether separating the supplements removes that risk is untested (Sperduto et al., 1993).
  • Accounting for depleting drugs: probenecid (a drug monograph), chlorpromazine (a review of drugs that promote riboflavin excretion) and barbiturates (a Linus Pauling Institute review) may lower status; a status check limits unrecognized depletion.
  • Anticipating bright yellow urine: this harmless effect (a Linus Pauling Institute review) prevents mistaking it for disease and affects urine color tests.

Therapeutic Protocol

Doses are cited to their sources; other parameters without a citation (timing, cycling, titration steps) reflect common practice.

  • Migraine protocol (adults): 400 mg riboflavin daily for three months (Schoenen et al., 1998; Chen et al., 2022). Guideline positions follow in Practical Considerations.
  • Comparator approach: Valproate 500 mg daily, a standard preventive drug, produced similar reductions in migraine frequency, duration and severity to 400 mg riboflavin, with more side effects on valproate (Rahimdel et al., 2015); neither is presented as the default.
  • Genotype-targeted blood pressure protocol: 1.6 mg riboflavin daily for 16 weeks in adults with MTHFR 677TT (Horigan et al., 2010; Wilson et al., 2013); 10 mg and 20 mg doses were registered for testing without posted results (NCT02463513; NCT05488106).
  • Status maintenance: The Recommended Dietary Allowance (RDA, intake meeting nearly all needs) is 1.3 mg for men and 1.1 mg for women (a National Academies report); 1.6 or 25 mg corrected low status in older adults (Madigan et al., 1998).
  • Popularizers: Jean Schoenen’s Liège group popularized 400 mg for migraine (Schoenen et al., 1998); Helene McNulty’s Ulster group the genotype-guided approach (McNulty et al., 2006); Rhonda Patrick lists 400 mg in a migraine supplement combination (FoundMyFitness episode).
  • Time of day: No best time is established; plasma and urinary riboflavin are lowest in the afternoon (Zempleni et al., 1996). Dosing with a meal is common practice, since food increases absorption (a drug monograph).
  • Half-life: Plasma half-life is about 66 to 84 minutes; storage is limited, mainly as FAD in liver, spleen, kidneys and heart (a drug monograph).
  • Single versus split doses: The migraine pilot gave 400 mg as a single oral dose (Schoenen et al., 1994), but only about 27 mg is absorbed per dose (Zempleni et al., 1996); divided doses are common practice.
  • Genetic polymorphisms: MTHFR 677TT adults responded to 1.6 mg daily and CC or CT adults did not (Horigan et al., 2010); no other variant informs dosing in adults.
  • Sex differences: Absorption and elimination did not differ by sex (Zempleni et al., 1996); the RDA differs (1.3 versus 1.1 mg), with 1.4 mg in pregnancy and 1.6 mg in lactation (a National Academies report).
  • Age: The RDA is the same from age 19 upward, but about half of free-living adults aged 65 and older had abnormal status at typical intakes (Madigan et al., 1998).
  • Baseline biomarker levels: Responses were largest with abnormal baseline EGRAC (Madigan et al., 1998) and lower baseline status in 677TT adults (McNulty et al., 2006).
  • Pre-existing health conditions: Malabsorption, liver disease and dialysis alter absorption or needs, and the usual dose for treating deficiency is 5 to 30 mg daily (a drug monograph).

Discontinuation & Cycling

  • Lifelong or short-term: Dietary riboflavin is a lifelong requirement; supplemental trial courses lasted 12 to 16 weeks (Schoenen et al., 1998; Wilson et al., 2013).
  • Withdrawal effects: None have been described; stopping riboflavin for several days did not impair motor capacity in a Parkinson’s series (Coimbra & Junqueira, 2003).
  • Tapering: No tapering protocol is described; plasma half-life is about 66 to 84 minutes (a drug monograph).
  • Cycling: No evidence supports cycling; trials dosed continuously, and blood pressure in 677TT adults was still elevated at follow-up four years after the original trial (Wilson et al., 2012).

Sourcing and Quality

  • Forms: Supplements contain riboflavin or riboflavin 5’-phosphate (Examine); dietary FMN and FAD are hydrolyzed to riboflavin before absorption, so no absorption advantage of the phosphate form is established (a National Academies report).
  • Third-party testing: In ConsumerLab testing, 19% of 26 B vitamin products contained far less or more of a vitamin than labeled, and cost did not predict quality (ConsumerLab news release).
  • Brands: Thorne Riboflavin 5’-Phosphate and Vitacost Vitamin B2 100 mg were among products in ConsumerLab’s review; test results require membership (ConsumerLab review).
  • Light protection: Light destroys riboflavin, with up to 50% of milk riboflavin lost within two hours of bright sunlight in clear glass (a Linus Pauling Institute review); opaque containers are used.
  • Capsule strength: Single-ingredient products such as Vitacost Vitamin B2 100 mg hold 100 mg, so 400 mg daily means four capsules (ConsumerLab review).
  • Food sources: One cup of 1% milk supplies 0.42 mg, a large egg 0.26 mg and an ounce of almonds 0.33 mg (a Linus Pauling Institute review).

Practical Considerations

Interaction with Foundational Habits

  • Sleep: Direction: indirect and unproven. A four-week trial of 43 adults found better sleep-quality scores with 100 mg each of vitamins B1 and B2 versus placebo, but the effect cannot be assigned to riboflavin alone (Tao et al., 2025). Sleep disruption was not described.
  • Nutrition: Direction: direct. Dairy, meat and fortified cereals supply most intake (a Linus Pauling Institute review); absorption rises with food, and a 400 µg folic acid supplement shifted more adults toward deficient status (Moat et al., 2003). A lower fat-to-carbohydrate ratio lowered the requirement in older adults (a National Academies report).
  • Exercise: Direction: raises requirement, no performance effect. Training increased the riboflavin needed to normalize status by about 20% in exercising women, while supplementation did not improve work performance or endurance in several studies, even with marginal status (a National Academies report).
  • Stress management: Direction: possibly blunting perceived stress; combination evidence only. The same four-week trial lowered perceived-stress scores but not anxiety scores versus placebo (Tao et al., 2025); the abstract reports no cortisol data, and the mechanism is unknown.

Monitoring Protocol & Defining Success

Baseline testing before supplementation would record riboflavin status (EGRAC), blood pressure and, for adults with the MTHFR 677TT genotype or hypertension, fasting homocysteine; genotype is established once by DNA testing. A migraine diary kept for at least one month provides the baseline attack count. Ongoing monitoring follows trial timepoints: repeat EGRAC and blood pressure at 12 to 16 weeks (Wilson et al., 2013), then every 6 to 12 months during supplementation, with the diary reviewed monthly through the first three months (Schoenen et al., 1998). Success is defined as EGRAC within the optimal range and, where a condition is targeted, change from the individual’s own baseline.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
EGRAC 1.26 or lower (optimal category per Jarrett et al., 2022) Marker the intervention is expected to change: riboflavin status EGRAC = erythrocyte glutathione reductase activation coefficient. Optimal category source: Jarrett et al., 2022. Conventional reference: below 1.2 acceptable, 1.2 to 1.4 low, above 1.4 deficient (a National Academies report). Needs fresh red cells; invalid in G6PD deficiency (an inherited red-cell enzyme gap).
Blood pressure Below 140/90 mmHg (trial goal per Horigan et al., 2010) Marker the intervention may change in the 677TT genotype, and safety check alongside antihypertensive drugs mmHg = millimeters of mercury. Goal source: Horigan et al., 2010. Standard reference range: below 120/80 mmHg. Home log or office readings.
Plasma homocysteine 5 to 15 µmol/L (standard reference range) Marker the intervention may change in the 677TT genotype Fasting sample; track change from own baseline. Fell from 16.1 to 12.5 µmol/L in 677TT adults on 1.6 mg daily (McNulty et al., 2006); reference ranges vary by laboratory.

Qualitative markers:

  • Migraine attacks, headache days and severity (diary)
  • Energy levels and fatigue
  • Sleep quality and perceived stress
  • Lip, mouth-corner and tongue condition (deficiency signs)
  • Urine color (bright yellow is expected with higher doses)

Emerging Research

  • Higher-dose genotype trial (RIBOGENE, NCT02463513): 1.6 or 10 mg versus placebo, 16 weeks, 243 677TT adults; registered completion 2017, status unknown, no results posted. Another abstract (81 adults, 10 mg) reported lower daytime systolic pressure only at baseline 125 mmHg or more (Ward et al., 2019). Full results: positive supports higher doses, null weakens them.
  • Vascular function trial (NCT05488106): 120 genetically at-risk adults, 1.6, 5 or 20 mg versus placebo, blood pressure primary outcome; registered completion June 2023, status unknown, no results posted. Positive: a dose-response; null: the Cochrane uncertainty stands.
  • Gambian pilot (NCT03151096): 133 adults in a riboflavin-deplete population, 5 mg versus placebo; terminated in 2019, no results posted. A positive result would extend the signal to deplete populations; a null result would narrow it to 677TT.
  • B vitamins and omega-3 for a brain-injury marker (NCT07312435): 96 older adults, 10 mg riboflavin with B6, B12, folate and omega-3 for three months, primary outcome neurofilament light chain (a blood marker of nerve injury); recruiting, primary completion March 2027. Positive: a first randomized brain-marker signal, not isolating riboflavin; null: cognitive benefit stays observational.
  • Magnesium plus riboflavin for post-concussion headache (NCT06260072): 108 participants, 400 mg each of riboflavin and magnesium for 14 days; the registered primary completion of 31 December 2025 has passed, status still listed as recruiting, no results posted. Positive: extends the headache signal beyond migraine; null: confines it.
  • Independent blood pressure confirmation: Cochrane calls for large, well-conducted trials (Bradbury et al., 2025); the two higher-dose trials above list the riboflavin producer dsm-firmenich as collaborator. A positive independent trial would lift the blood pressure item above Low, a null trial would remove it.
  • Weakening directions in cells and worms: leukemia-cell dependency (Bjelosevic et al., 2025), ferroptosis resistance (Skafar et al., 2026) and longer worm lifespan with depletion (Yerevanian et al., 2022) could weaken the case for supplementation if confirmed in humans.

Conclusion

Riboflavin (vitamin B2) is an essential vitamin that cells use to make energy and to recycle antioxidants. For health- and longevity-oriented adults who already obtain enough from food, the evidence for added benefit is limited and uneven. The strongest human data concern migraine prevention in adults at amounts far above the dietary requirement, where results are mostly favorable but mixed in children and combination products. A blood pressure effect in people with a particular common gene variant has been reported mainly by a single research group, and an independent review judged the pooled evidence very uncertain. Other possible benefits, such as protection of the lens, mood, memory or longer life, rest on one trial of riboflavin combined with niacin, food-intake associations, small uncontrolled reports or animal studies, and laboratory studies point in opposite directions on lifespan.

Documented risks are minor. High amounts turn urine bright yellow, and mild gastrointestinal (stomach and bowel) upset has been reported without a clear excess over placebo. One trial linked riboflavin combined with niacin to a rare form of lens clouding. Laboratory findings about light-driven damage and cancer-cell growth remain unconfirmed in people. No upper intake limit has been set.

The evidence base is small and comes mainly from academic and hospital research groups, with the trials showing the largest effects traced to the same few investigators, and the higher-dose trials list a riboflavin producer as collaborator. No direct revenue from riboflavin was identified for the professional societies that endorse it.

Top - Benefits - Risks - Protocol